Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
BACKGROUND: The role of dysglycemia as an additional risk factor for atrial fibrillation (AF) is controversial. Therefore, it was of interest to assess risk factors for incident AF in a large, representative population of patients with cardiovascular risk factors and impaired glucose tolerance but...
Auteurs principaux: | Latini, R, Staszewsky, L, Sun, J, Bethel, M, Disertori, M, Haffner, S, Holman, R, Chang, F, Giles, T, Maggioni, A, Rutten, G, Standl, E, Thomas, L, Tognoni, G, Califf, R, McMurray, J |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2013
|
Documents similaires
-
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
par: Preiss, D, et autres
Publié: (2013) -
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
par: Califf, R, et autres
Publié: (2008) -
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
par: Preiss, D, et autres
Publié: (2012) -
Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
par: Mcmurray, J, et autres
Publié: (2011) -
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
par: Krum, H, et autres
Publié: (2010)